Skip to content Skip to footer
Reprogenetica
Reprogenetica
Κλείστε Ραντεβού
Close

Research & Development

Reprogenetica S.A is a private commercial company specialized in reproductive genetics, preimplantation genetic testing (PGT), and advanced assisted reproduction technologies. The company integrates clinical practice with innovation in genomics,  and embryology with a strong track record in translational research and collaboration in national and EU-funded projects.

Current involvement in Research and Innovation actions

Currently undertaking a national research grant to undertake early diagnosis of HPV-related epithelial hyperplasia through a new epigenetic test. Code OPS TA 5180519 (SHINE). The project focuses on the development and clinical validation of a novel genetic diagnostic test, commercially named SHINE, which is based on the analysis of five epigenetic methylation markers for the detection of cervical precancerous lesions (CIN2/3), using qmSP-PCR in minimally invasive samples (clinician-collected or self-collected).

The test aims to:
Icon
Strengthen molecular diagnosis alongside hrHPV testing and cytology
Icon
Reduce false-positive results and unnecessary invasive procedures
Icon
Increase population coverage through self-sampling and non-invasive approaches

Scientific evidence relies on:

  • The role of DNA methylation as a biomarker for CIN2/3
  • The WHO strategy for cervical cancer elimination
  • The limitations of current practice (hrHPV testing, cytology, colposcopy).

Key methylation markers studied internationally include FAM19A4, miR124, CADM1, MAL, and PAX1, though no test currently integrates all simultaneously.The proposed methodology is expected to demonstrate strong clinical utility for the accurate triage of women with CIN2/3, supporting targeted treatment and reducing both costs and inequalities in cervical cancer screening. Additionally, the methylation testing market shows strong growth potential, offering significant opportunities for commercialization.

Team’s involvement
in past projects

Project: Pilot clinical trial of maternal spindle transfer (MST) for the treatment of repeated in vitro fertilization failures in couples with idiopathic infertility.

In this trial members of the team performed MST by transferring metaphase II spindles from the patients’ oocytes into the previously enucleated donor oocytes, followed by intracytoplasmic sperm injection, in vitro embryo culture, blastocyst biopsy, and vitrification. Only euploid blastocysts were considered for embryo transfer. Reconstructed oocytes produced embryos capable of implanting, developing to term and producing apparently healthy newborns/children. However, claims concerning the efficacy of MST with respect to infertility treatment would be premature considering the limitations of this study. Importantly, mtDNA reversal was detected in one child born after MST, a finding with possible implications for mitochondrial replacement therapies.

Clinical Award Oral presentation/EHSRE Annual meeting 2012.

This work by Christopikou, D, gained clinical award at ESHRE Annual Meeting 2012. The work was among the first to non-invasively use time-lapse imaging to measure the timing of the first and second cleavage divisions and the transition between the 2- and 4-cell stages and correlate these and other morphological parameters with the chromosome copy number or the presence of single or multiple aneuploidies ascertained by cleavage stage biopsy at the 8-cell stage and single cell analysis by array CGH (DOI:10.1016/S1472-6483).